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ABSTRACT

The marked increase of bacteria that are resistant to clinically relevant antibiotics in recent years
has sparked a push in the development and discovery of novel antibiotics. Complementary to
this, the identification of novel antibiotic targets is also of great interest. The lysine biosynthesis
pathway is an ideal candidate for these efforts because its product is an essential amino acid.
Lysine cannot be synthesized by humans and thus poses minimal risk of side effects if synthesis
is targeted. The penultimate product in the lysine biosynthesis pathway, meso-DAP, is also a key
component of the gram-negative bacterial cell wall peptidoglycan layer. The L,Ldiaminopimelate aminotransferase (DapL) pathway, a recently discovered variant in the lysine
biosynthetic pathway is especially of interest because it has been identified in only about 13% of
bacteria. Because of its narrow distribution in bacteria, it could be an ideal target for the
development of narrow spectrum antibiotics. A key enzyme in the pathway, DapL is a
homodimer that catalyzes the conversion of tetrahydrodipicolinate (THDP) to L,Ldiaminopimelate (L,L-DAP) in a single, reversible transamination reaction. While this enzyme is
essential in plants that contain the pathway, it is not directly known whether the same is true for
bacteria that contain the pathway. In order to evaluate DapL as a target for the development of
narrow spectrum antibiotics, genetic and phenotypic characterizations must be performed. This
project evaluated DapL from Verrucomicrobium spinosum, a close relative of Chlamydia, as a
potential target in the development of antibiotic compounds. It assessed the essentiality of the
VsdapL gene via targeted knockouts using the CRISPR/cas9 system, providing evidence
supporting the essentiality of the gene in bacteria. It also evaluated putative antagonistic ligands
using a comprehensive and comparative molecular dynamics (MD) software package – DROIDS
(Detecting Relative Outlier Impacts in Dynamic Simulations) 2.0, providing insight into the
dynamic behavior of the DapL protein and identifying a correlation between total effect on
protein dynamics in silico and inhibition measured in vitro.
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BACKGROUND ON THE LYSINE BIOSYNTHETIC PATHWAY

Recent years in medicine and technology have seen a marked increase in the incidence of
multidrug resistant bacterial infections. Bacteria that cause these infections and develop such
resistance, for example commonly among the Pseudomonas, Chlamydia, or Staphylococcus
genera, can grow and propagate in the presence of some of the strongest antibiotic compounds
currently known (Ventola, 2015). Antibiotic resistance can be acquired in different ways – some
bacteria develop antibiotic resistance via accumulation of random mutations that allow it to
propagate in the presence of an antibiotic while others develop resistance through transfer of
external genetic factors (e.g. horizontal transfer of antibiotic resistance genes between
organisms) (Munita & Arias, 2016). The rise of antibiotic resistant bacteria, even against
antibiotics of last resort, highlights the need for novel targets in and approaches to antibiotic
research and development to treat human disease.
Of the hundreds of amino acids found in nature, only twenty are ubiquitous in protein synthesis
(twenty are deemed proteogenic). Of those twenty proteogenic amino acids nine are nutritionally
essential for humans as they cannot be synthesized in vivo and must be obtained through diet.
The pathways and proteins involved in the synthesis of these nine essential amino acids are
attractive targets for antibiotic development because, in theory, targeting them would cause
minimal toxicity in the patient other than their intended bactericidal effect.
Lysine is one of such essential amino acid, it cannot be synthesized by humans and the pathway
is an attractive research target for antibiotic development. In organisms that have the ability,
lysine biosynthesis occurs via one of two pathways: the alpha-aminoadipic pathway (AAA) is
commonly found in yeast, fungi and some archaea while the diaminopimelate pathway (DAP) is
employed by photosynthetic organisms and most prokaryotes (Nishida et al., 1999; Velasco,
10

Leguina, & Lazcano, 2002) and is the focus of this study. The DAP pathway has three main
steps: (1) Conversion of aspartate to tetrahydrodipicolinate (THDP) by intermediary enzymes
LysC, AspD, DapA, and DapB (Figure 1A, abbreviations in Figure 1), (2) conversion of THDP
to meso-diaminopimelate (m-DAP), and (3) conversion of m-DAP to Lysine by LysA (Figure 1).
There are four known variants of the DAP pathway, distinguished by differences in m-DAP
generation: the acyl-diaminopimelate pathways (Figure 1B), the meso-diaminopimelate
dehydrogenase (Ddh) pathway (Figure 1C), and the recently identified l,l-diaminopimelate
aminotransferase (DapL) pathway (Hudson, Singh, Leustek, & Gilvarg, 2006) (Figure 1D).

Figure 1: The Lysine Biosynthesis Pathways

(A) The synthesis of THDP from aspartate, (B) The acyl pathway, (C) the Ddh pathway, (D) the
DapL pathway, and (E) the reversible transamination reaction catalyzed by DapL.
11

Abbreviations: DapC, acyl-diaminopimelate aminotransferase; DapE, acyl-diaminopimelate
deacylase; DapD, 2,3,4,5-tetrahydropyridine-2,6-dicarboxylate-N-acyl-transferase; DapF, acyldiaminopimelate deacylase, DapL, L,L-diaminopimelate aminotransferase; Ddh,
diaminopimelate dehydrogenase; LysA, diaminopimelate decarboxylase. Adapted from (Triassi
et al., 2014).

In the acyl-diaminopimelate pathways, most commonly found in bacterial species, DapD and
DapC enzymes produce acetylated (via acetyl-CoA) or succinylated (via succinyl-CoA)
intermediates from THDPA, followed by production of L,L-DAP by DapE and its conversion to
m-DAP by DapF. The acyl pathways constitute two of the four DAP pathway variants. The third
variant of the pathway, the Ddh pathway converts THDPA directly to m-DAP in a single reaction
by Ddh. Lastly, the DapL pathway, identified in plants and some bacterial species and first
identified in Arabidopsis thaliana, utilizes DapL in place of the DapC, DapD, DapE, DapF, or
Ddh enzymes found in other organisms in the conversion of THDP to m-DAP. It converts THDP
to L,L-DAP via a single, direct, reversible transamination reaction after which the DapF enzyme
converts L,L-DAP to m-DAP for further use (Hudson et al., 2005, 2006) (Figure 1E).
The lysine biosynthetic pathway is also a potential antibiotic target because of its involvement in
downstream pathways, specifically in cell wall construction in most bacteria. In Gram-negative
bacteria, m-DAP is in the third position of a peptide stem that links layers of Nacetylglucosamine – N-acetylmumaric acid disaccharides to form the peptidoglycan cell wall; in
Gram-positive bacteria, lysine is in the center of the linking peptide chain between layers of
disaccharides (Hutton, Perugini, & Gerrard, 2007) (Figure 2). Without the cross-linking of
peptidoglycan, the cell wall loses stability and is unable to adequately protect the cell and
maintain separation of the internal and external environment. Without this stability afforded by
12

the cell wall, the bacterium will lose stability and eventually rupture. Because of its critical role
in peptidoglycan crosslinking and protein synthesis as well as its lack of presence in mammals
(specifically humans), the lysine biosynthetic pathway is an attractive target for the development
of novel antibiotics with minimal predicted side effects.

Figure 2: Peptidoglycan Structure and Organization

(A) Structure of the monomeric subunit of peptidoglycan, with the cross-linking highlighted in
the grey box. (B) Cross-linking by meso-DAP (Gram negative) and Lysine (Gram positive)
bacteria. Adapted from (Triassi et al., 2014).
The key enzyme in the DapL pathway, L,l-diaminopimelate aminotransferase (DapL) is a
homodimer whose two subunits are each ~40 kD in size (Figure 4A) (Biasini et al., 2014). The
enzyme in its native form contains two active sites and functions on a hinge; only one site is
active at a time due to a conformational change in the other site when bound with a substrate.
Each subunit is composed of a major and minor arm, the major arm composing the dimer
interface for each subunit. The DapL enzyme, via a classic bimolecular ping-pong mechanism
13

(Velick & Vavra, 1962), transfers an amino group plus a proton and electron pair from a donor
molecule to an acceptor molecule. In aminotransferases, this process occurs in two steps. First,
the amino group from the donor molecule forms a Schiff based structure with a pyridoxal-5’phosphate (PLP) molecule that is covalently bonded to the conserved lysine residue in the active
site (Figure 3) followed by the transfer of the amino group to the acceptor molecule (Liepman &
Olsen, 2004). As previously mentioned, the DapL enzyme catalyzes a reversible transamination
reaction; a glutamate acts as the donor molecule and THDP acts as the acceptor in the forward
reaction while L,L-DAP acts as the donor molecule and 2-oxoglutarate acts as the acceptor in the
reverse reaction (Hudson et al., 2006).

Figure 3: Model of V. spinosum DapL
A

B

The Verrucomicrobium spinosum DapL protein (VsDapL), modeled by SWISS-MODEL, is a
homodimer with two active sites. (A) The full enzyme colored by subunit, one active site
highlighted by a black box. (B) The active site close view with key residues (Y74, E77, and N294
on the chain opposite the pocket and Y134, I43, G44, R390, N189, and K111) colored in pink
and the conserved K251 that binds with PLP (pyridoxal-5’-phosphate) colored in red.
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As previously mentioned, distribution of the lysine biosynthetic pathway variants is widespread
across organisms. The alpha-aminoadipic pathway (AAA) is commonly found in yeast, fungi and
Archaea while the diaminopimelate pathway (DAP) is employed by photosynthetic organisms
and most prokaryotes (Nishida et al., 1999; Velasco et al., 2002). In addition, most bacterial
species employ the acyl-DAP pathway, a handful of bacterial species employ the Ddh pathway,
and plants and some other bacterial species employ the DapL pathway (Nishida et al., 1999;
Velasco et al., 2002). The DapL pathway specifically has been identified in the genomes of 13%
of all bacteria (Triassi et al., 2014), a narrow distribution containing bacterial species of medical
and biotechnological relevance, plants, and some archaea.
Among the bacterial species employing the DapL pathway, those belonging to the phyla
Chlamydophila, Treponema, Leptospira, and Bacteroides are especially of interest. Each contain
organisms of extreme relevance and understanding the critical metabolic pathways of those
species would provide beneficial insight. For example, Chlamydia trachomatis is a pathogen and
the causative agent of one of the most reported sexually transmitted diseases in the United States
and the leading cause of infection-mediated blindness worldwide (Mishori, McClaskey, &
WinklerPrins, 2012). It is a Gram negative, obligate intracellular bacterium with high rates of
lateral gene transfer between serotypes and largely uncharacterized genetic properties (Mabey,
2008). Treponema pallidum is the causative agent of human Syphilis, an infection that has
maintained its status as a significant cause of human disease regardless of the availability of an
effective treatment (Burstain, Grimprel, Lukehart, Norgard, & Radolf, 1991). T. pallidum is also
commonly found as a secondary infection in HIV-immunocompromised patients, and
complications from general infection include neurosyphilis and retinitis (Berry, Hooton, Collier,
& Lukehart, 1987). Infection with Leptospira interrogans causes leptospirosis, an illness with a
15

wide range of symptoms presenting with flu-like symptoms and occasionally progressing to a
hemorrhagic fever (Ansdell, 2012; Lindsay, Bone, & Fuller, 2010). In severe cases it is treated
with intravenous antibiotics and kidney and liver dialysis treatments. Bacteroides fragilis is
commonly found as a microbiotic component of the human gastrointestinal tract, but causes
significant anaerobic infections upon a breach of that system including infections of the head,
neck, pelvis, soft tissues, and nervous system (Finegold & Sussman, 2002). In addition,
enterotoxigenic B. fragilis causes significant gastrointestinal illness (Wexler, 2007). Each of the
aforementioned species are the causative agents of significant and serious human disease, and
each of the aforementioned species either employ the DapL pathway or have a close relative in
the same genus that employs the DapL pathway for lysine biosynthesis.
Also contained in the distribution of the DapL pathway is the PVC superphylum, a monophyletic
group consistently recovered in 16S rRNA trees containing phyla Planctomyces,
Verrucomicrobia, Chlamydiae, Lentisphaerae, and candidates Poribacteria and OP3 that span
interesting groups. Planctomyces are commonly found in aquatic and terrestrial ecosystems
(Dedysh, Pankratov, Belova, Kulichevskaya, & Liesack, 2006; Vergin et al., 1998). Species from
this phylum have reported properties for useful biotechnological application in numerous areas,
ranging from formaldehyde detoxification to denitrification and the removal of ammonia from
water sources (Wagner & Horn, 2006). Chlamydiae, members of whom were previously
mentioned, is commonly identified as containing extremely successful human pathogens, but it
also contains some commensal and environmental species. Verrucomicrobia contains widely
abundant environmental microorganisms and is suspected to comprise up to 10% of the total
bacteria in soil (Sangwan, Chen, Hugenholtz, & Janssen, 2004). Though Verrucomicrobia are
not known to be pathogenic, several species live in association with other eukaryotes. There is
16

also evidence that Verrucomicrobium spinosum utilizes the non-flagellar type III secretion
system like some chlamydial species, a secretion system known to mediate interaction between
the bacteria that contain it and the target eukaryotic cells (Pallen, Beatson, & Bailey, 2005).
Interestingly, numerous eukaryotic genes have been identified in the genomes of these
organisms, indicating a high rate of lateral gene transfer between these bacterial species and their
eukaryotic host cells. Though species of Verrucomicrobia have been found independent of any
eukaryotic cells, no free-living species of Chlamydia or Poribacteria have been found. The PVC
superphylum contains a group of bacterial species with interesting properties as well as highly
relevant bacterial species that should be isolated and investigated further for biotechnological
and clinical application.
Though its distribution is narrow, the DapL pathway is employed by species with unique
properties and those of biotechnological and clinical importance. A large majority of species in
the PVC superphylum employ an anaerobic metabolism, are obligate intracellular organisms, or
are pathogenic to humans (e.g. Chlamydia trachomatis). As such, manipulation of most
organisms that employ the DapL pathway is a formidable task. However, Verrucomicrobium
spinosum is a phenotypic outlier. It is a slow-growing, heterotrophic bacterium that is nonpathogenic to humans and the closest free-living relative of C. trachomatis based on examination
of both widely distributed proteins and shared inserts (Griffiths & Gupta, 2007). Evidence of
peptidoglycan in the cell wall of Chlamydia was also recently discovered and validated
(Packiam, Weinrick, Jacobs, & Maurelli, 2015; Pilhofer et al., 2013), further supporting the use
of V. spinosum in the development of a model system to evaluate the DapL pathway for the
development of narrow-spectrum therapeutics for bacterial infections.

17

We hypothesized that inhibition of L,L-diaminopimelate aminotransferase will cause a
bactericidal effect through prevention of peptidoglycan crosslinking and protein synthesis
because of the involvement of both meso-diaminopimelate/lysine in the peptidoglycan
crosslinking of the bacterial cell wall and the status of lysine as a proteogenic amino acid. In this
thesis, the essentiality of the gene encoding the DapL protein in Verrucomicrobium spinosum
was assessed as a step toward the development of a model system and the dynamic behavior of
the enzyme in its native state was compared to its behavior when complexed with antagonistic
lead compounds in comprehensive, comparative molecular dynamics simulations.

18
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7.1

CHAPTER 1: Developing a Model System in Verrucomicrobium spinosum
INTRODUCTION

DapL is a good target for narrow spectrum antibiotic development because of both its limited
distribution in prokaryotes and its dual involvement in lysine biosynthesis and peptidoglycan
crosslinking of the cell wall. The DapL pathway was identified in approximately 13% of the
genomes of all bacteria and archaea, including those of interest detailed previously. DapL has
been proven essential in plants that contain the pathway; in instances where the gene is
eliminated or inactivated the plant cannot survive without 2,6-diaminopimelate (DAP)
supplementation (Dobson, Girón, & Hudson, 2011). While the same has been assumed true for
bacteria that contain the DapL pathway, it has never experimentally investigated and ambiguity
surrounding both lysine biosynthesis and aminotransferases in bacteria also underscores the need
to direct investigation. For example, evidence of two pathways for lysine biosynthesis has been
found in two bacterial species; B. fragilis and C. thermocellum contain both the DapL and Ddh
pathways (Hudson et al., 2011). However, no other bacterial species to date have been identified
as containing dual pathways. In addition, some aminotransferases are proven to be promiscuous,
they can act on multiple substrates. It is currently not known if the same may occur in bacteria
that employ the DapL pathway as the sole producer of lysine, or if it is fully dependent on a
functional dapL. The development of a model system that can be cultured and is non-pathogenic
is an ideal approach to study the essentiality of the pathway and develop inhibitors of the DapL
enzyme.
As the chosen bacterium in this project, Verrucomicrobium spinosum employs the DapL
pathway as its sole producer of lysine and m-DAP for downstream peptidoglycan crosslinking
(Nachar et al., 2012). It is a Gram-negative, heterotrophic, slow growing organism commonly
19

found in freshwater environments. While it is known to associate with eukaryotic hosts, V.
spinosum is non-pathogenic to humans. This organism was also chosen because
Verrucomicrobium is a member of the PVC superphylum (Wagner & Horn, 2006), composed of
phyla Planctomycetes, Verrucomicrobia, Chlamydiales, and Lentisphaerae, of whom are host to
medically and biotechnologically important species.
Genetic manipulation of V. spinosum has also been investigated in one laboratory; it was
previously manipulated via random transposon insertion (Domman, Steven, & Ward, 2011) with
sufficient recovery and antibiotic resistance. In addition, the presence of recombination proteins
A (RecA) and R (RecR), involved in replication-associated and homologous recombination,
respectively in the annotated genome, and the suspected high lateral gene transfer rate between it
and other organisms suggest success in further genetic manipulation. However, the whole
genome sequence indicates no evidence of endogenous plasmids, and there has been no data to
support the replication and maintenance of a broad host-range plasmid in this organism. The
presence of genetic recombination enzymes and successful Tn5 mutagenesis with V. spinosum
indicate that, while many properties of the organism are largely unknown, it is a good candidate
for genetic knockout to test essentiality, and for further genetic and phenotypic studies (Nachar
et al., 2012).
One of such techniques for example, homologous recombination is a type of biological genetic
recombination where two independent nucleotide sequences are exchanged, guided by basepairing interactions of the homologous nucleotide sequences. This event is mediated by
recombination enzymes. The DNA double helix separates at the homologous site and one strand
creates a heteroduplex joint with the matching strand on the other DNA molecule. After cleavage
and rejoining, a portion of one DNA molecule is swapped with the other molecule (Alberts et al.,
20

2002). Its application in gene editing simply involves the use of a desired insert of choice (e.g. a
selectable antibiotic resistance marker nucleotide sequence) flanked by sequences homologous to
the targeted insertion site (e.g. dapL). Transformation and selection for the desired phenotype is
expected to result in a mutated, non-functional dapL.
Another genetic editing tool, CRISPR (Clustered Regularly InterSpaced Palindromic Repeats)
has become very popular in recent years. First identified as a proteolytic enzyme and a
component of bacterial immune defense mechanisms, CRISPR was characterized as a region of
the bacterial genome where the 3’ end was marked with direct repeats spaced with a 32nucleotide spacer and a CRISPR-associated (cas) gene directly next to the repeating region
(Ishino, Shinagawa, Makino, Amemura, & Nakata, 1987). The spacer sequence was identified as
a sequence homologous to a region targeted by Cas (Garneau et al., 2010; Jansen, Embden,
Gaastra, & Schouls, 2002). The CRISPR/Cas system is fully self-contained and can be expressed
in a vector with only the direct repeats, cas, and targeting sequence (Sapranauskas et al., 2011).
The most common current tool is the Type II CRISPR/cas9 locus. There are three essential
regions in the genetic makeup of this tool: (1) a tracrRNA gene, (2) the cas gene, and (3) the
CRIPSR repeat-spacer array. The CRISPR repeat-spacer array is transcribed into pre-crRNA, the
cas gene is transcribed and translated into the Cas protein (in this case Cas9), and the tracrRNA
gene is transcribed into tracrRNA. Post-transcription processing by cas9, tracrRNA, and an
RNase modifies the pre-crRNA to form a set of unique tracrRNA/cas9/crRNA complexes that
then cleave target DNA sequences based on an alignment with the tracrRNA sequence
(Chylinski, Le Rhun, & Charpentier, 2013) (Figure 4). The tracrRNA/crRNA complex is
sometimes replaced with a single gRNA (the guide RNA) for ease of build and distribution. This
guide RNA contains the targeting sequence (like the tracrRNA) as well as the sequences
21

necessary for interaction with the cas protein (Mali et al., 2013). Target genes are modified by
either random insertion due to DNA breakage or by introducing a DNA sequence into the cell for
incorporation after DNA breakage and the activation of DNA native repair mechanisms.

Figure 4: cas9 targeting VsdapL

VsdapL

CGCCGTTCTTGGAGAAGCTACGGAACTCAAT

GCGGCAAGAACCTCTTCGATGCCTTGAGTTA

CGCCGTTCTTGGAGAAGCTA
GCGGCAAGAACCTCTTCGAT

CGGAACTCAAT
GCCTTGAGTTA

cas9 introducing a double-stranded break in target DNA, as guided by the gRNA upon
association with cas9.
Here, methods of generating a V. spinosum mutant deficient in dapL are reported, with the
purpose of providing data that supports the essentiality of the gene in bacteria that employ the
DapL pathway as the sole producer of lysine and peptidoglycan crosslinking.
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7.2
7.2.1

METHODS
Strains, Growth, and Transformation Conditions

V. spinosum DSM 4136T, obtained from the American Type Culture Collection (ATCC #43997)
was cultured on M13 minimal media. For all transformations, a stationary culture (measured at
OD600 0.3) was sub-cultured in 5 ml and grown to exponential phase at an OD600 0.15 (about 30
hours) before electrocompetent cell preparation. The cells were pelleted, washed twice in cold
sterile dH20 and twice in cold sterile 10% glycerol before resuspension in ~100 ul cold sterile
10% glycerol. Electroporation occurred with two pulses at 1.0 kV, followed by resuspension in
equal volume (typically 5 ml) 200 ug/ml DAP-supplemented M13 and recovery of 2 hours and
24 hours before plating of 100 ul on M13 agar supplemented with Dap and antibiotic. Plates
were incubated for ~one week at 30°C in a humid environment for colony formation.
7.2.2

Homologous Recombination

Two genetic knockout approaches were tested: gene interruption and gene replacement with a
selectable marker (neomycin phosphatase NptII, a kanamycin resistance gene) (Figure 5). To
introduce a gene interruption, nptII was cloned, in frame, in the center of dapL to generate a
knockout cassette. To introduce a full gene replacement, nptII was closed directly between dapL
upstream and dapL downstream flanking regions to generate a knockout cassette. The knockout
cassette was then cloned into replication-deficient pUC57 (lacking the proper origin of
replication) vector before transformation into V. spinosum. The vectors were constructed by Bio
Basic Inc. custom ordering services (https://www.biobasic.com/). Both knockout cassettes were
also PCR amplified and purified for linear transformation into V. spinosum. To inhibit the native
restriction endonucleases, an inhibitor was also transformed into V. spinosum during each
experiment (“TypeOneTM Restriction Inhibitor,” n.d.). After transformation and recovery, cells
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were plated on media supplemented with DAP and Kanamycin for nutrient supplementation and
antibiotic selection, respectively.
Homologous recombination

Figure 5: Recombination Schemes
A

B

B.

A.
vsdapL

nptII

vsdapL

US-vsdapL

vsdapL

vsdapL

nptII

nptII

DS-vsdapL

vsdapL
vsdapL

vsdapL

US-vsdapL

nptII

DS-vsdapL

(A) Illustrated knockout via homologous recombination (double X’s) mediated by a gene
interruption cassette containing sequences homologous to the VsdapL sequence and (B)
illustrated knockout via homologous recombination mediated by a gene replacement cassette
containing sequences homologous to regions directly upstream (‘US’) and downstream (‘DS’) of
the VsdapL sequence.
7.2.3

CRISPR/cas9

The first implementation of the CRISPR/cas9 system in V. spinosum used the pCas9 plasmid
(Jiang, Bikard, Cox, Zhang, & Marraffini, 2013). A target sequence was constructed in the form
of forward and reverse-complementary oligos, annealed together, and digested with BsaI. The
digested sequence was ligated into the BsaI site of pCas9 between the direct repeating segments.
Clones were screened for proper insert sequence via restriction digest and Sanger sequencing
before transformation and expression testing in V. spinosum.
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The second implementation of the CRISPR/cas9 system was an in vitro experiment utilizing a
gRNA synthesis protocol and transfection-ready Cas9 from ThermoFischer (Liang, Potter,
Kumar, Ravinder, & Chesnut, 2017). A target sequence in DapL was identified and primers were
synthesized to include a T7 promoter and the beginning of the target sequence (F primer) as well
as a tracrRNA constant region corresponding to Cas9 (R primer). gRNA design to target V.
spinosum dapL is depicted in Figure 6. After PCR synthesis of the gRNA template DNA, in vitro
transcription and RNA purification was performed for high quality, high concentration gRNA.
The gRNA was briefly incubated with Cas9 in a ratio of 1.2:1 gRNA:Cas9 for complex
association prior to transformation into V. spinosum with either gene interruption cassettes, gene
knockout cassettes, or no addition (Figure 7). After transformation, OD600 was tracked during
recovery and before plating.

PCR assembly
schema
Figureof6:gRNA
gRNA
Design

A.

T7 promoter

crRNA/tracrRNA constant region (80 nt)

Target

5’–TAATACGACTCACTATAGCGCCGTTCTTGGAGAAGCTAGTTTTAGAGCTAGAA...GTCGGTGCTTTT–3’
Universal F primer

Universal R primer

Target F primer
Target R primer

B.
Target F: TAATACGACTCACTATAGCGCCGTTCTTGGAGAAGCTA
Target R: TTCTAGCTCTAAAACTAGCTTCTCCAAGAACGGCG

The design of guideRNA targeting the VsdapL gene containing (A) a T7 promoter region (blue),
target sequence (red), and crRNA constant region (black) with primer alignment below. (B)
Target forward and reverse primers designed to amplify the constant region (black), target
sequence (red), and T7 promoter (blue).
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Figure 7: Transformation Outcomes
B.

A.
Scenario 2
Scenario 1

½ vsdapL

vsdapL

vsdapL

½ vsdapL

nptII

vsdapL

nptII

US

US-vsdapL

vsdapL

US-vsdapL

½ vsdapL

½ vsdapL

nptII

nptII

DS

DS-vsdapL

DS-vsdapL

(A) Illustrated knockout via homologous recombination (double X’s) mediated by a gene
interruption cassette containing sequences homologous to the vsdapL sequence after double
stranded breakage mediated by Cas9 and (B) illustrated knockout via homologous
recombination mediated by a gene replacement cassette containing sequences homologous to
regions directly upstream (‘US’) and downstream (‘DS’) of the vsdapL sequence after double
stranded breakage mediated by Cas9.
7.2.4

Growth Experiment

Post-transformation cells were resuspended in equal volume (to pre-transformation preparation)
M13 or DAP-supplemented M13 and their growth was tracked over 48 hours. The cells from
each transformation condition, after 48 hours recovery in 200 ug/ml DAP-supplemented M13
were pelleted, washed twice in M13, and resuspended in 50 ug//ml kanamycin-supplemented
M13 or DAP and kanamycin-supplemented M13 for growth tracking.

7.2.5

Scanning Electron Microscopy Imaging

The cell fixing protocol was obtained from Dr. Anutthaman Parthasarathy at RIT. 1.5 ml cells
from each culture were reserved after two and twenty-four hours of recovery, pelleted, and stored
in ~10 ul M13 media at 4° C until fixing. The pellet was resuspended, the entire contents were
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pipetted onto a glass slide cover and soaked in 2% glutaraldehyde solution for two hours. Excess
solution was decanted off after the culmination of two hours and dehydrated in a graded ethanol
series with ten-minute washes of 50%, 70%, 80%, 95%, and 100% ethanol solutions. Samples
were stored with parafilm at room temperature until imaging at 10kV scanning electron
microscopy.
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7.3
7.3.1

RESULTS
Phenotypic Analyses of V. spinosum

V. spinosum has a slow growth rate spanning several days and density-limited growth in liquid
culture (Figure 8). It has a doublimg time of about 20 hours. The growth curve indicates optimal
timing for genetic manipulation occurs between 12 and 48 hours post-inoculation, during its
exponential growth phase and at an OD600 between 0.05 and 0.20. For adequate growth on solid
media, V. spinosum also needs optimal humidity, minimal media, and a low cell density if
plating from a liquid culture.

Figure 8: V. spinosum Growth Curve
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Absorbance at 600 nm of V. spinosum liquid culture over time at 30° C. It has a relatively short
lag phase before entering exponential growth for a period between 10 and 60 hours after
inoculation until an OD600 of 0.25, after which point cell death starts to prevail.
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VsdapL, previously cloned into pBAD33 in the Hudson lab, successfully complements E. coli
mutants deficient in the Dap D/E enzymes of the lysine biosynthetic pathway (Figure 9).
Mutants complemented with the VsdapL construct grew at the same rate as mutants without
dapL supplemented with DAP.

Figure 9: VsDapL Complementation Assay

Absorbance at 600 nm of cultures of DapD/E deficient E. coli mutants supplemented with DAP,
complemented with the VsDapL enzyme, and without any supplements. Optical density
measurements were taken over the course of seven hours.

However, no knockout attempts in V. spinosum to investigate dapL requirement via homologous
recombination were successful. Of the forty experiments performed testing homologous
recombination as a knockout tool, fifteen resulted in no growth upon plating, ten resulted in
lawns or smearing on plates because of bacterial over-saturation, and any remaining that were
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recoverable lacked the target genotype (evidence of the kanamycin resistance gene or the dapL
via confirmatory PCR). Most genotype screens resulted in proper controls with no result in the
test case (Figure 10).

Figure 10: Examples of Unsuccessful Knockouts
A.

B.

A

C.

KB+ (-)C (-)C (+)C T

B

C

Images of M13 agar plates from homologous recombination experiments that show (A)
lawn/smearing of cells due to culture oversaturation (B) recoverable cell phenotypes for
screening and (C) genetic screens via PCR that show a lack of target genotype.

No recoverable phenotypes were propagated from the experiments with pCas9. Cells that
showed potential phenotype lacked the presence of any genotype indicating either plasmid
maintenance or knockout. In addition, the V. spinosum genome contains evidence of a potential
chloramphenicol acetyltransferase gene (Table 6), which may confer chloramphenicol resistance
and thus eliminate pCas9 dependence under chloramphenicol selection.
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A high concentration of extremely pure RNA was generated for use with the platinum cas9
nuclease in the in vitro experiments (Figure 11), with a working stock concentration of ~1600
ng/ul. Subsequent complex formation with cas9 and transformation into V. spinosum, however,
resulted in no recoverable target phenotypes. Plating was standardized to yield single colonies in
the controls (Figure 12), but no other growth was observed in the test conditions.

Figure 11: gRNA quality and quantity as determined by NanoDrop
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Absorbance at 10nm of synthesized gRNA samples, measured by Nanodrop. The concentration
was measured at 1636.52 ng/ul, with an A260/A280 of 1.881 and A260/A230 of 2.342.
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Figure 12: V. spinosum standard plating

Wild-type V. spinosum plated on M13 for single colonies from a
liquid culture after a transformation experiment.

In liquid culture after the Cas9 transformation experiments, V. spinosum transformants grew both
without and with the presence of DAP (Figure 13). The growth trajectories differ slightly, but
there was minimal or no cell death or lag phase of growth. Upon introduction to kanamycin, cells
transformed with the knockout cassettes died slightly slower than the controls (Figure 14).
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Figure 13: Growth curve of cas9 knockouts
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Absorbance at 600 nm of mutant and wild type V. spinosum. Samples included cultures
transformed with a cas9/guideRNA complex, the complex combined with a gene replacement or
gene interruption cassette, or no transformed sample cultured in either (A) M13 or (B) M13
supplemented with DAP.
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Figure 14: Kanamycin survival of cas9 knockouts
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Absorbance at 600 nm of mutant and wild type V. spinosum from a DAP-supplemented recovery.
Samples included cultures transformed with (A) a cas9/guideRNA complex or no transformed
sample or (B) the complex combined with a gene replacement or gene interruption cassette,
cultured in M13 supplemented with kanamycin or M13 supplemented with DAP and kanamycin.
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7.3.2

SEM Imaging

V. spinosum was successfully imaged between 60,000X and 80,000X magnification. Prosthecae
were clearly visible on the surface of the wild type cells and the size ranged from 0.75 to 1.5 um
in size (Figure 15). The regular morphology of most cells was an oblong double-ball shape,
while some were only one ball (not shown). There was some irregularity in the imaging (Figure
16), however the majority of cells had consistent morphology in prosthecae and an oblong cell
shape. Cells that congregated together still retained morphological definition and boundaries
were easily discernible.

Figure 15: Two hours post transformation of wild type cells
A.

B.

One cell each of wild type V. spinosum imaged at (A) 64,100X and (B) 51,600X magnification.
Scale bars represent 1 um, each.
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Figure 16: Twenty-four hours post transformation of wild type cells
A.

B.

A cluster of (A) 20 wild type V. spinosum cells imaged at 8,720X magnification and (B) 6 wild
type cells imaged at 27,900X magnification. Scale bars represent 2 um and 5 um, respectively.

V. spinosum cells transformed with the cas9/gRNA targeting complex and gene interruption
cassette were also successfully imaged after two and twenty-four hours of recovery. While the
cellular sizes were consistently between 0.75 and 1.5 um, there was a wide range of
morphological phenotypes present. After two hours (Figure 17), some cells were elongated and
smooth with little to no protrusions or prosthecae on the surface. Other cells were amorphous,
and indication of lysed cells was present. After twenty-four hours the phenotypic irregularity
increased significantly (Figure 18). The surface composition of the cells exhibited more ridges
and roughness and there were little to no typically oblong or double-ball morphologies present.
Most cells were rounded and amorphous with signs of lysis and structural integrity failure.
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Figure 17: Two hours post transformation of mutant candidates from the cas9 complex and gene
interruption cassette
A.
B.

C.

(A) One V. spinosum cell at 67,500X magnification, scale bar at 500 nm. (B) V. spinosum cell at
311,000X magnification, scale bar at 200 nm. And (C) a cluster of V. spinosum cells at 41,900X
magnification, scale bar at 1 um.
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Figure 18: Twenty-four hours post transformation of mutant candidates from the cas9 complex
and gene interruption cassette
A.
B.

C.

D.

(A) One V. spinosum cell at 74,300X magnification, scale bar representing 500nm. (B) One V.
spinosum cell at 57,400X magnification, scale bar respresenting 1 um. (C) Two V. spinosum
cells at 27,800X magnification, scale bar representing 2 um, and (D) three V. spinosum cells at
19,800X magnification, scale bar representing 2 um.
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Cells transformed with the cas9/gRNA complex and gene replacement cassette were, once again,
successfully imaged after two and twenty-four hours of recovery. Dramatic morphological
irregularities were present. Two hours post-transformation, cells were seen largely congregated
together (Figure 19). Most cells were amorphous and round, lacking the typical oblong shape
and prosthecae. The surfaces of the cells were also rough and exhibited signs of folding and
concavity. Remnants of cells were captured, indicating the possibility of lysis. Twenty-four
hours post-transformation, evidence of phenotypic irregularity increased in frequency (Figure
20). Most of the imaged cells were fully unstructured, amorphous, and/or concaved. Cells that
congregated together were so shapeless that definition and cellular boundaries were difficult to
discern. Evidence of structural failure was also present.
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Figure 19: Two hours post transformation of mutant candidates from the cas9 complex and gene
replacement cassette
A.
B.

C.

D.

(A) Two V. spinosum cells at 43,900X magnification, scale bar representing 1 um. (B) a cell
fragment at 134,000X magnification, scale bar representing 200 nm. (C) a group of cells at
17,500X magnification, scale bar representing 2 um. (D) a group of cells at 65,200X
magnification, scale bar representing 1 um.
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Figure 20: Twenty-four hours post transformation of mutant candidates from the cas9 complex
and gene replacement cassette
A.

C.

B.

D.

(A) One V. spinosum cell at 54,500X magnification, (B) a cell or cell group at 56,400X
magnification, (C) a cell or cell group at 60,700X magnification, and (D) a group of cells at
57,200X magnification. Scale bars all represent 1 um.
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Imaging was only avaible twenty-four hours post-tranformation for cells transformed with excess
amounts of the cas9/gRNA complex. Though the sample was limited to one time point, major
phenotypic differences were once again present in high quality images (Figure 21). Cells formed
long shapeless structures with no visible cellular definition aside from the exterior. The cell
surface was concave and folded onto itself, indicating signs of structural failure. A handful of
cells with normal morphology was found, but they were interpersed through the largely irregular
and amorphous phenotypes.
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Figure 21: Twenty-four hours post transformation of mutant candidates from the cas9 complex
A.

B.

C.

D.

(A) One V. spinosum cell at 40,800X magnification, (B) a group of cells at 57,800X
magnification, (C) two cells at 44,800X magnification, and (D) a cell or group of cells at
65,300X magnification. Scale bars each represent 1 um.
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7.4

DISCUSSION

Verrucomicrobium spinosum has unique growth characteristics requiring a low cell density in
liquid culture and a humid environment for plating, characteristics that can hinder model system
development. With the proper standardization, however, manipulation and development of this
organism into a model is certainly possible. Growth to an OD600 of ~0.1 for electrocompetent cell
preparation, resuspension in equal volume post-electroporation, and plating of 100 ul results in
the best plated phenotype with visible single colonies. The cells exhibited low transformation
efficiency, as evidenced by the lack of successful transformations and lack of target genotypes or
phenotypes, so alternative methods of transformation could be explored, including the use of
conjugation instead of electroporation or increased cell concentration for electroporation.
When targeting dapL with a replication deficient vector and knockout cassette, the presence of
colonies but lack of genotype, lack of phenotype, or lack of colonies altogether indicates that
either no transformation, no recombination, or single recombination events were occurring. It
can be theorized that a lack of secondary selection for the second recombination event combined
with selection against recombinants via loss of the lysine biosynthetic pathway created a difficult
environment for the integration of the gene. Any successfully recombined mutants were
hypothetically instantly killed, or their growth inhibited and propagation of those mutants
subsequently impossible. Only mutants with a functional dapL could grow, and those that also
recombined the selectable marker could then propagate on antibiotic. Future work to generate a
knockout via homologous recombination should include a secondary selectable marker, like a
sucrose sensitivity gene, on the plasmid for selection against to then select for the second
recombination event (Wu, Ren, & Huntley, 2015).
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The in vitro CRISPR/cas9 system did show promise, however due to time limitations testing was
halted at the culmination of the project. Transfection ready cas9 is optimized for eukaryotic cells,
but these experiments show that it is also functional, and its use is realistic for bacteria that
exhibit interesting properties or with unknown genetics. The presence of nuclear localization
signals in the enzyme do not interfere with its activity upon the lack of a nucleus. In addition, the
gRNA synthesis protocol was incredibly consistent and prolific, resulting in high yields of highly
pure RNA for transformations. The consistency of the tool aided in developing a model system
in an organism that is not widely studied and the tool has future potential to save time and money
when targeting putatively essential genes.
In the case of DapL, though the naked controls successfully grew, a mutant was not recovered
upon plating with for DAP and antibiotic selection. The organism’s growth in liquid culture,
however, showed signs of success. Though no mutants were isolated, and no growth was
observed, the differential death rate of V. spinosum transformants in liquid culture was an
indication of potential successful recombination of the selectable marker at the desired insertion
site. In addition, scanning electron microscopy conducted in conjunction with knockout
experiments indicates that V. spinosum was experiencing mutations that affected its phenotype.
When transformed with the Cas9 complex, regardless of the presence or absence of a knockout
cassette, cells became amorphous and congregated together in inseparable clumps. A qualitative
investigation with SEM imaging also showed evidence of structural failure of the cell walls via
lack of prosthecae, concavity, irregularity, and folds. The samples that included the knockout
cassettes exhibited a higher frequency of highly irregular cellular phenotypes, with more
frequent and severe structural failures. The presence of atypical cells in the test cases indicates
potential failures in cell wall integrity, perhaps resulting from the failure of peptidoglycan
45

crosslinking. Based on this evidence, recovery of a mutant may not be possible. However, when
combined with the differential growth of transformants in liquid culture, the data do support the
essentiality of dapL and the efficacy of it as an antibiotic target.
Future work in evaluating VsDapL (as a model for any DapL enzyme) as an antibiotic target
should account for the gaps detailed above. First, a vector that definitively replicates in V.
spinosum should be identified, as complementing the organism with a functional dapL prior to a
knockout would mitigate the extremely toxic effects indicated by previous experiments. A
method to explicitly test the efficacy of the Cas9 system should be developed; the dapL sequence
on a vector in E. coli could be targeted with the same gRNA to accommodate any
transformation-associated issues and directly test the Cas9 system. In addition, dynamic
approaches to measure a knockdown or knockout in liquid culture, like RNA-interference,
should be explored to accommodate the growth properties of V. spinosum. It would also provide
a refined view of the toxicity of inhibiting DapL without eliminating the functionality of the gene
and live/dead staining and fluorescence microscopy could be utilized to provide further insight
into the effect of the knockout on individual cells. Lastly, future work should assess
transformation efficiency and recovery methodology in V. spinosum to clarify these conclusions
and provide more insight.
Overall, the experiments to generate a genetic knockout of dapL in V. spinosum with the goal of
using it as a model in the development of narrow spectrum antibiotics were largely exploratory.
They consisted of extensive troubleshooting, trial, and error. However, they did succeed in
identifying tools and developing standardized protocols in the growth, preparation, and
manipulation of V. spinosum for use in future experiments and laid the foundation for supporting
the essentiality of dapL in the organism and, by association, all bacteria that employ the pathway.
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8
8.1

CHAPTER 2: Comparative Molecular Dynamics Simulations of DapL
INTRODUCTION

Computational biology is a rapidly expanding field that allows researchers to experiment in
silico; they can perform simulations and construct models of biological molecules and processes
to gain insight prior to, during, and after experimentation. Molecular dynamics, a field of
computational chemistry, is rapidly expanding with application in computational biology. In
short, it applies molecular mechanics methods to predict the motion of a molecule in an
environment over a time course. Molecular mechanics, approaching molecules as collections of
balls and springs to represent the atoms and bonds respectively, calculates the potential energy of
the molecular system and readjusts the position of each atom until it obtains the lowest energy
state (Lewars, 2003).
Molecular dynamics applies Newton’s laws of motion and molecular mechanics in a stepwise
manner, calculating the different forces exerted on each atom and adjusting the position for
energy minimization over time, usually on a femtosecond time scale. The forces exerted on an
atom can be defined in bond stretching, angle bending, torsion, van der Waals potentials, or
electrostatic potentials and are generally referred to as defined force fields of inter- and intramolecular interactions for a given molecule type or category (Jensen, 2007). There are numerous
molecular dynamics packages available for use, one of such is titled "AMBER" (Assisted Model
Building with Energy Refinement). It is both a molecular dynamics package and a set of predetermined molecular mechanical force fields (tested and determined parameters that dictate the
interaction of biomolecules) that can be used to simulate biomolecule movement (CASE et al.,
2005). At the culmination of the molecular dynamics calculations, the stepwise updated atomic
coordinates, velocities of movement, and accelerations are processed to generate trajectories that,
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when combined with statistical mechanics, describe the time evolution of the molecular system.
In computational biology, molecular dynamics can be applied to nearly anything including
proteins, DNA, and RNA (with limitations of size and stability) and, when combined with other
techniques like protein docking, can provide novel insight into biomolecule form and function.
Protein docking is a molecular modeling technique that non-covalently associates a molecule
(usually a ligand) and a protein to determine a three-dimensional complex. The interaction
between two molecules is complex; the technique must account for the complexities of the
protein (e.g. amino acid interactions and hydrophobicity), the molecule (e.g. flexibility and
charge), and the combination of the two (e.g. electrostatic forces and hydrogen bonds). In order
to model this interaction, docking protocols utilize a combination of a search algorithm and
scoring function. The search algorithm creates a set of molecular configurations that is evaluated
by the scoring function, a number of mathematical models that predict the strength of each
interaction in the set. Depending on the size of the system and computational limitations,
different search algorithms and scoring functions can be used. For larger molecules, docking is
limited to molecular mechanics but others may employ Monte Carlo methods or genetic
algorithms combined with various scoring functions including knowledge-based or consensus
scoring (Hernández-Santoyo, Tenorio-Barajas, Altuzar, Vivanco-Cid, & Mendoza-Barrera, 2013;
Jensen, 2007). One of such docking programs, AutoDock Vina has a largely computationallyoptimized scoring function and a search algorithm that requires a user-defined search space for
fast and accurate processing (Trott & Olson, 2010). Though complex, docking has various
applications, including structure-guided drug design and in vitro protein-protein or proteinnucleic acid interactions.
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Here, a comprehensive, comparative molecular dynamics simulation package, DROIDS
(Detecting Relative Outlier Impacts in Dynamic Simulations) 2.0 (Babbitt, Mortensen, Coppola,
Adams, & Liao, 2018), was used in conjunction with AutoDock Vina to provide insight into the
binding dynamics of putative inhibitory lead compounds. Developed as a GPU-based package,
DROIDS can be used on any linux computer containing graphics cards (e.g. gaming computers
or specifically designed research computers). Because of advances in graphics card development,
molecular dynamics calculations can now be performed at speeds orders of magnitude faster and
biologically relevant calculations are now realistic expectations. Utilizing Amber16 and
Ambertools17 packages (CASE et al., 2005), cpptraj vector trajectory analysis (Roe &
Cheatham, 2013), the R software suite for statistical analysis, and UCSF Chimera visualization
tools (Pettersen et al., 2004) in GUI-based pipeline, DROIDS calculates the local modes of
interaction between the residues of a given structure, simulating the interaction between each
molecule, for two macromolecules over a set time course for a user-designated number of
replications. It then compares the dynamics of the two macromolecules and presents a statistical
analysis of the differences in dynamic movement in the context of atomic fluctuations from the
mean position. Because this information is presented in graphs, figures, and structure coloration,
there is great potential for interpretation and dissemination across a broad audience. In addition,
the implementation of DROIDS in a user-interface platform with accessible graphics-card based
system dependencies harnesses usability for any given user. The methods and results presented
here can be applied for the basic scientist and modified to not only supplement laboratory
experiments, but also provide a rational guide in their development.
Because of its presence in key medically and biotechnologically relevant organisms, DapL is an
attractive target for antibiotic, herbicide, and algacide development. Previous work identified
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antibiotic lead compounds in a comprehensive screening analysis that inhibited the DapL
enzyme from A. thaliana, L. interrogans, C. reinhardtii, and V. spinosum. Four compounds
specifically effectively inhibited the activity of the V. spinosum DapL (VsDapL) enzyme,
derived from four classes with different structural elements (McKinnie et al., 2014). However,
the analysis relied solely on experimental data and manual screening of a 30,000-compound
library and an alternative method to screen the database to a smaller set of compounds would be
beneficial.
To date, the crystal structure of VsDapL has not been published. However, due to sufficient
sequence similarity with related DapL enzymes (i.e. Arabidopsis thaliana PDB: 3EI7,
Chlamydia trachomatis PDB: 3QGU, and Chlamydomonas reinhardtii PDB: 3ASA) it is
possible to construct a homology-based model and identify active-site residues. When compared
to the unpublished, experimentally determined structure from Anthony Weatherhead at the
University of Canterbury, the model is sufficient for analyses (RMSD of 1.15 and Q-Score of
0.825) to make inferences about the form, function, and activity of the enzyme. To demonstrate
the scope and applicability of the DROIDS pipeline, test the accuracy of DROIDS in drawing
conclusions, and provide refined insight into the screening analysis (McKinnie et al., 2014), and
demonstrate the use of a modeled enzyme in such analyses, the effect of the four identified
inhibitory lead compounds on the molecular dynamics of the VsDapL model was analyzed and
trends in the resulting dynamics change were identified.
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8.2
8.2.1

METHODS
Multiple Sequence Alignment

Multiple sequence alignment was constructed in MEGA of the DapL protein sequence from V.
spinosum (PDB: WP_09961032.1), A. thaliana (UniProt: Q93ZN9), C. trachomatis (UniProt:
G4NMX8), and C. reinhardtii (UniProt: A8IW39). Sequences were aligned via MUSCLE
algorithm. Conserved active site loops and residues were identified from the multiple sequence
alignment.
8.2.2

Structure Stabilization Testing

Structure stability and conformation testing was performed by Jamie Mortensen at RIT during
the initial DROIDS pipeline development and prior to version 1 release. The solvated structures
were each subjected to 1000 cycles of minimization using a steepest-descent algorithm, followed
by an 80-picosecond heating step where the temperature was gradually raised from 0 to 300K
and then an 80-picosecond simulation allowing for the potential energy of the molecule to reach
an equilibrium, followed by a 120-nanosecond sampling simulation. Atomic coordinates were
calculated every 0.002 picoseconds and recorded every 0.2 picoseconds. Temperature and
pressure were held constant for the equilibration and subsequent runs.
8.2.3

Compound Preparation

Lead compounds identified by (McKinnie et al., 2014) (Figure 22) were exported in SMILES
format from the Chembridge database (“ChemBridge | Home,” n.d.) and the 3D coordinates were
generated with the CORINA server (Sadowski, Gasteiger, & Klebe, 1994; Schwab, 2010;
“Welcome to MN-AM | MN-AM,” n.d.).
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Figure 22: Antagonist Lead Compounds Identified for Use

The ID number, chemical formula, and structure for the four antagonistic lead compounds
against DapL identified by and adapted from McKinnie et al. and assigned for use in the
molecular dynamics analyses.
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8.2.4

Molecular Docking

Three dimensional compounds were docked onto the DapL active site with the PyRX interface
for Autodock Vina (Dallakyan & Olson, 2015; Trott & Olson, 2010). The best ranked
conformation, with the best binding affinity reported, was chosen for each respective molecular
dynamics calculation run in DROIDS. For each run, the protein-ligand complex, the protein, and
the ligand in its proper conformation identified by Vina were exported in PDB format. The
resulting three files each were used.
8.2.5

DROIDS Settings and Run Times

The structures solvated structures were each subject to 1000 cycles of minimization using a
steepest-descent algorithm, followed by a 100-picosecond heating step to 300K, followed by a 5nanosecond equilibration step to allow for the potential energy of the molecule to reach an
equilibrium before 300 production sampling runs of 0.5 nanoseconds. Temperature and pressure
were held constant for the equilibration and subsequent runs.

8.3
8.3.1

RESULTS
Multiple Sequence Alignment

Loops lining the active site in V. spinosum were identified between residue numbers 249 and 261
(Loop A), as well as those from the opposing chain between residues 66 and 81 (Loop B), and
291 and 297 (Loop C). In addition, key conserved active site residues were identified as residue
numbers 43, 44, 74, 77, 111, 134, 189, 251, 294, 390 (Figure 23).
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Figure 23: VsDapL Multiple Sequence Alignment
V.spinosum
C.trachomatis
A.thaliana
C.reinhardtii

1
1
1
1

---------------------------------------------------------MAL
----------------------------------------------MTLPCFMDFRWFMK
MSSTHQLVSSMISSSSSTFLAPSNFNLRTRNACLPMAKRVNTCKCVATPQEKIEYKTKVS
----------------------MQLNVRSTASGARSSTRSRRMTAVVQAVAQRAGTIDVQ

V.spinosum
C.trachomatis
A.thaliana
C.reinhardtii

4
15
61
39

INENFLKLKAGYLFPEIARRVKAFTEGNPEAAQRLIRCGIGDVTEALPEAVRYAMHEAVD
RNPHFVSLTKNYLFADLQKRVAQFRLENPQH--TVINLSIGDTTQPLNASVAEAFASSIA
RNSNMSKLQAGYLFPEIARRRSAHLLKYPDA--QVISLGIGDTTEPIPEVITSAMAKKAH
RNENFGKLRAGYLFPEIARRRKAHQEKNPDA--KIISLGIGDTTEPLPKYIADAMAKAAA

**

Loop B+

V.spinosum
C.trachomatis
A.thaliana
C.reinhardtii

64
73
119
97

ELGNRSTFKGYGPEQGYDFLRNAIADNDYKARGLPIEADEIFISDGSKCDTGNILDIFGQ
RLSSPTTCRGYGPDFGLPALRQKLSEDFY--RGF-VDAKEIFISDGAKVDLFRLLSFFGP
ELSTIEGYSGYGAEQGAKPLRAAIAKTFY--GGLGIGDDDVFVSDGAKCDISRLQVMFGS
GLATREGYSGYGAEQGQGALREAVASTFY--GHAGRAADEIFISDGSKCDIARIQMMFGS

V.spinosum
C.trachomatis
A.thaliana
C.reinhardtii

124
130
177
155

GNTIAITDPVYPVYVDTNVMIGNTGEADEN-GAYAGLVYLKCTPENGFVPDIPQE-KADL
NQTVAIQDPSYPAYLDIARL-----------TGAKEIIALPCLQENAFFPEFPEDTHIDI
NVTIAVQDPSYPAYVDSSVIMGQTGQFNTDVQKYGNIEYMRCTPENGFFPDLSTVGRTDI
KPTVAVQDPSYPVYVDTSVMMGMTGDHNG--TGFDGIEYMVCNPDNHFFPDLSKAKRTDI

V.spinosum
C.trachomatis
A.thaliana
C.reinhardtii

182
179
237
213

IYLCYPNNPTGAVATRPQLEAWVKYARENGSVLLYDAAYEAFIQDPTIPHSIFEIEGARD
LCLCSPNNPTGTVLNKDQLRAIVHYAIEHEILILFDAAYSTFISDPSLPKSIFEIPDARF
IFFCSPNNPTGAAATREQLTQLVEFAKKNGSIIVYDSAYAMYMSD-DNPRSIFEIPGAEE
IFFCSPNNPTGAAATRAQLTELVNFARKNGSILVYDAAYALYISNPDCPKTIYEIPGADE

* *

*

*

*

Loop C+

Loop A

V.spinosum
C.trachomatis
A.thaliana
C.reinhardtii

242
239
296
273

CAIEFRSFSKNGGFTGVRCAYVVIPKSLMGRKKNGEAQALHPLWSRRHSTKFNGASYIVQ
CAIEINSFSKPLGFAGIRLGWTVIPQEL----TYADGHFVIQDWERFLSTTFNGASIPAQ
VAMETASFSKYAGFTGVRLGWTVIPKKL----LYSDGFPVAKDFNRIICTCFNGASNISQ
VAIETCSFSKYAGFTGVRLGWTVVPKAL----KYANGEPVHADWNRVMTTCFNGASNIVQ

V.spinosum
C.trachomatis
A.thaliana
C.reinhardtii

302
295
352
329

KGAEALYTDEGKSQTKAL--IEHYMGNAALLVEACKNAGLSVFGGVNAPYVWVG-CPAGL
EAGVA-----GLSILPQLEAIHYYRENSDLLRKALLATGFEVFGGEHAPYLWVKPTQANI
AGALACLTPEGLEAMHKV--IGFYKENTNIIIDTFTSLGYDVYGGKNAPYVWVH-FP-NQ
AGGLACLQPEGLKEMNAM--IKFYKENAQILKTTFTEMGFSVYGGDDAPYIWVG-FP-GK

V.spinosum
C.trachomatis
A.thaliana
C.reinhardtii

359
350
408
385

TSWQMFDKMLNEANVVITPGSGFGSAGEGYFRISAFNSRANVEEVCRRIAALK---SDRDLFDFFLREYHIAITPGIGFGRSGSGFVRFSSLGKREDILAACERLQMAPALQS
SSWDVFAEILEKTHVVTTPGSGFGPGGEGFVRVSAFGHRENILEACRRFKQLYK--PSWDVFAEILERCNIVTTPGSGFGPAGEGFVRASAFGSRENILEAVRRFKEAYGKRN

*

*

*

Alignment of the VsDapL sequence to reference sequences. * denotes conserved active site
residues, “-----” denotes residues in loops lining the active site, and + denotes a contribution
from the opposing chain.
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8.3.2

Structure Stability Testing

Based on RMSD (Root Mean Square Deviation) calculations of the fluctuation of the alphacarbons of each amino acid from their mean positions, the homodimer and monomer forms of the
DapL protein were compared (Figure 24). As a monomer, the early sampling of vsDapL
coordinates indicate a RMSD value of 2. Over time, however, the RMSD increases and nears 5.
On the contrary, the vsDapL homodimer stabilizes just above a RMSD value of 1 for the
duration of the sampling time.

Figure 24: VsDapL Dimer and Monomer Testing

A. Root Mean Square Deviation (RMSD) values for the fluctuation of the alpha-carbons of each
amino acid from the mean position of the backbone were calculated for the molecular dynamics
sampling runs of the B. DapL monomer and C. DapL homodimer.
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8.3.3

Molecular Docking

Upon docking, the hydrazide molecule settled in a best conformation with a binding affinity of 7.6 kcal/mol. There was a total of five conformations found, all associating in various positions
across the entire protein as indicated by the RMSD values when compared to the best identified
conformation. The binding affinity ranged from -7.6 kcal/mol to -5.2 kcal/mol. The molecular
structure for the best docked conformation indicated the hydrazide molecule bound close to the
active site (Figure 25; Table 1).
The rhodanine molecule settled in a best conformation with a binding affinity of -8.3 kcal/mol.
There was a total of nine conformations found, all associating in various positions across the
entire protein as indicated by the RMSD values when compared to the best identified
conformation. The binding affinity ranged from -8.3 kcal/mol to -6.7 kcal/mol. The molecular
structure for the best docked conformation indicated the rhodanine molecule docked in the minor
arm of one active site (Figure 26; Table 2).
The barbiturate molecule settled in a best conformation with a binding affinity of -7.6 kcal/mol.
There was a total of nine conformations found, all associating in various positions across the
entire protein as indicated by the RMSD values when compared to the best identified
conformation. The binding affinity ranged from -7.6 kcal/mol to -7.2 kcal/mol. The molecular
structure for the best docked conformation indicated the barbiturate molecule docked along the
outer edge near the active site (Figure 27; Table 3).
The thiobarbiturate molecule settled in a best conformation with a binding affinity of -6.4
kcal/mol. There was a total of nine conformations found, all associating in various positions
across the entire protein as indicated by the RMSD values when compared to the best identified
conformation. The binding affinity ranged from -6.4 kcal/mol to -5.7 kcal/mol. The molecular
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structure for the best docked conformation indicated the thiobarbiturate molecule docked on the
outer surface of the protein (Figure 28; Table 4).
Based on identified contacts, the four small molecule antagonists bound to different locations on
DapL. Hydrazide bound to the majority of residues in the active site, including the catalytic
lysine (residue 251). Rhodanine and thiobarbiturate did not bind near the active site whatsoever,
and barbiturate bound near the active site but not directly in it. Rhodanine docking resulted in the
best binding affinity of the four compounds. Docking of hydrazide and barbiturate resulted in
similar binding affinities, and thobarbiturate resulted in the least impactful docking (Figure 29).
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Figure 25: Hydrazide Docking Structure

The structure of one hydrazide molecule (red) docked near one active site of VsDapL (blue).
Table 1: Hydrazide Docking Statistics
Ligand

Binding Affinity rmsd/ub
(kcal/mole)

rmsd/lb

VsDapL_1 -7.6

0

0

VsDapL_2 -7.4

7.064

2.225

VsDapL_3 -5.5

6.538

2.595

VsDapL_4 -5.3

26.033

23.535

VsDapL_5 -5.2

2.206

1.78

Docking results for the hydrazide and VsDapL association. The lowest energy structure is
reported first, and the RMSD of the following structures is reported as compared to the position
of the first conformation.
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Figure 26: Rhodanine

The structure of one rhodanine molecule (red) docked near one major arm of VsDapL (blue).
Table 2: Rhodanine Docking Statistics
Ligand

Binding Affinity (kcal/mole)

rmsd/ub

rmsd/lb

VsDapL_1

-8.3

0

0

VsDapL_2

-8.1

2.053

1.579

VsDapL_3

-7.6

3.294

2.564

VsDapL_4

-7.2

5.09

3.438

VsDapL_5

-7.1

2.24

1.756

VsDapL_6

-6.9

18.955

16.319

VsDapL_7

-6.8

4.915

3.176

VsDapL_8

-6.7

16.581

15.273

VsDapL_9

-6.7

4.339

2.866

Docking results for the rhodanine and VsDapL association. The lowest energy structure is
reported first, and the RMSD of the following structures is reported as compared to the position
of the first conformation.
59

Figure 27: Barbiturate

The structure of one barbiturate molecule (red) docked near one active site of VsDapL (blue).
Table 3: Barbiturate Docking Statistics
Ligand

Binding Affinity (kcal/mole)

rmsd/ub

rmsd/lb

VsDapL_1

-7.6

0

0

VsDapL_2

-7.5

9.86

7.352

VsDapL_3

-7.4

8.358

2.628

VsDapL_4

-7.4

3.049

1.801

VsDapL_5

-7.3

9.42

7.243

VsDapL_6

-7.3

5.406

3.305

VsDapL_7

-7.3

5.49

3.092

VsDapL_8

-7.2

23.098

17.59

VsDapL_9

-7.2

5.499

2.922
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Docking results for the barbiturate and VsDapL association. The lowest energy structure is
reported first, and the RMSD of the following structures is reported as compared to the position
of the first conformation.

Figure 28: Thiobarbiturate

The structure of one thiobarbiturate molecule (red) docked near the bottom of one VsDapL
active site (blue).
Table 4: Thiobarbiturate Docking Statistics
Ligand

Binding Affinity (kcal/mole) rmsd/ub

rmsd/lb

VsDapL_1

-6.4

0

0

VsDapL_2

-6.3

2.188

1.166

VsDapL_3

-6.2

4.465

3.288

VsDapL_4

-6.2

30.347

29.039

VsDapL_5

-6.1

30.138

28.76

VsDapL_6

-5.9

26.064

24.954
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VsDapL_7

-5.9

26.127

25.066

VsDapL_8

-5.8

27.866

25.529

VsDapL_9

-5.7

29.549

28.307

Docking results for the thiobarbiturate and VsDapL association. The lowest energy structure is
reported first, and the RMSD of the following structures is reported as compared to the position
of the first conformation.
Docking
results
Figure 29: Binding Summary

Compound

Binding Affinity (KD)

Interacting Residues

Hydrazide

-7.6

43*, 74*, 111*, 110, 134*, 189*, 217, 250 , 251**, 259, 294*

Rhodanine

-8.3

12, 15, 16, 135, 138, 156, 161, 361, 379

Barbiturate

-7.6

17, 18, 21, 77*, 78, 287, 290

Thiobarbiturate

-6.4

91, 95, 221, 231, 247, 316, 317

* Active site residue
** Catalytic residue

The binding affinity for and residues that interact with each identified compound used in this
study. *Residues that are associated with the active site. **Catalytic residue.
8.3.4

Comparative Molecular Dynamics

Statistically significant differences in fluctuations between the unbound VsDapL molecule and
VsDapL bound to hydrazide were found upon completion of the DROIDS pipeline (Figure 30).
The fluctuation (dFLUX) and statistical profiles were asymmetric across the protein, they were
not replicated between the two subunits (e.g. the dFLUX of residues 1-10 on chain A was
different than the dFLUX of residues 1-10 on chain B). A full list of residues that experienced
statistically significant differences in fluctuation are presented in Figure 38. The catalytic lysine
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in the active site corresponding to the bound molecule was dampened and its activity stabilized,
and the catalytic loop in both pockets was destabilized as some conserved residues were
dampened while others were softened with an amplification in fluctuation. In fact, every active
site chain was destabilized upon hydrazide association, some residues in each active site loop
were dampened while others were activated. The statistically significant differences in
fluctuation were primarily along the active site and dimer interface.

Figure 30: DROIDS Plot and Images, VsDapL and Hydrazide
A.

B.
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300 x 0.2ns explicit solvent molecular dynamic simulation of wild type V. spinosum DapL
enzyme compared to DapL associated with a hydrazide molecule. (A) Average atom fluctuation
profiles (top plot), signed symmetric Kullback-Leibler (KL) divergences in local atom fluctuation
distributions, collected from the N, CA, C and O atoms from each amino acid on the polypeptide
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backbone (middle plot), and P values from a Benjamini-Hochberg corrected KolmogorovSmirnov (KS) test indicating significant differences in dynamics is also shown (bottom plot). The
KL divergences in local atom fluctuation distributions are shown color mapped to temperature
on the protein structure with red indicating softer regions with amplified fluctuation and blue
indicating stabilized regions with dampened fluctuation (B) across the entire structure and (C)
on the active site. (C) P values from the KS test indicating significant differences in dynamics.

Statistically significant differences in fluctuations between the unbound VsDapL molecule and
VsDapL bound to rhodanine were also found upon completion of the DROIDS pipeline (Figure
31). The fluctuation (dFLUX) and statistical profiles were asymmetric across the protein, they
were not replicated between the two subunits (e.g. the dFLUX of residues 1-10 on chain A was
different than the dFLUX of residues 1-10 on chain B). A full list of residues that experienced
statistically significant differences in fluctuation are presented in Figure 38. The catalytic lysine
in the active site corresponding to the bound molecule was dampened and its activity stabilized,
and the conserved catalytic loop in that pocket was destabilized as some residues were dampened
while others were softened with an amplification in fluctuation. The catalytic loop in the second
pocket (not corresponding to the location of the bound compound) was significantly dampened.
At least one residue on each active site loop was dampened, but some loops did not have any
corresponding amplification in activity. The statistically significant differences in fluctuation
were broadly spread across the protein, not limited to any region or interface. However, both
active sites hosted the highest magnitude residue dampening across the entire protein.
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Figure 31: DROIDS Plot and Images, VsDapL and Rhodanine
A.
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300 x 0.2ns explicit solvent molecular dynamic simulation of wild type V. spinosum DapL
enzyme compared to DapL associated with a rhodanine molecule. (A) Average atom fluctuation
profiles (top plot), signed symmetric Kullback-Leibler (KL) divergences in local atom fluctuation
distributions, collected from the N, CA, C and O atoms from each amino acid on the polypeptide
backbone (middle plot), and P values from a Benjamini-Hochberg corrected KolmogorovSmirnov (KS) test indicating significant differences in dynamics is also shown (bottom plot). The
KL divergences in local atom fluctuation distributions are shown color mapped to temperature
on the protein structure with red indicating softer regions with amplified fluctuation and blue
indicating stabilized regions with dampened fluctuation (B) across the entire structure and (C)
on the active site. (C) P values from the KS test indicating significant differences in dynamics.
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Statistically significant differences in fluctuations between the unbound VsDapL molecule and
VsDapL bound to barbiturate were found upon completion of the DROIDS pipeline (Figure 32).
The fluctuation (dFLUX) and statistical profiles were asymmetric across the protein, they were
not replicated between the two subunits (e.g. the dFLUX of residues 1-10 on chain A was
different than the dFLUX of residues 1-10 on chain B). A full list of residues that experienced
statistically significant differences in fluctuation are presented in Figure 38. Though there was
destabilization in all three active site loops in both pockets, there was more reported evidence of
statistically significant amplification than dampening. In addition, neither conserved catalytic
residue in either pocket was affected.

Figure 32: DROIDS Plot and Images, VsDapL and Barbiturate
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300 x 0.2ns explicit solvent molecular dynamic simulation of wild type V. spinosum DapL
enzyme compared to DapL associated with a barbiturate molecule. (A) Average atom fluctuation
profiles (top plot), signed symmetric Kullback-Leibler (KL) divergences in local atom fluctuation
distributions, collected from the N, CA, C and O atoms from each amino acid on the polypeptide
backbone (middle plot), and P values from a Benjamini-Hochberg corrected KolmogorovSmirnov (KS) test indicating significant differences in dynamics is also shown (bottom plot). The
KL divergences in local atom fluctuation distributions are shown color mapped to temperature
on the protein structure with red indicating softer regions with amplified fluctuation and blue
indicating stabilized regions with dampened fluctuation (B) across the entire structure and (C)
on the active site. (C) P values from the KS test indicating significant differences in dynamics.

Statistically significant differences in fluctuations between the unbound VsDapL molecule and
vsDapL bound to thiobarbiturate were found upon completion of the DROIDS pipeline (Figure
33). The fluctuation (dFLUX) and statistical profiles were asymmetric across the protein, they
were not replicated between the two subunits (e.g. the dFLUX of residues 1-10 on chain A was
different than the dFLUX of residues 1-10 on chain B). A full list of residues that experienced
statistically significant differences in fluctuation are presented in Figure 38. All three loops in
the pocket corresponding to the bound molecule were dampened, but only two experienced
correlating amplification. In addition, three loops were amplified in the second pocket, but only
one experienced correlating dampening. Only one of the two conserved catalytic residues were
significantly dampened, the other was unaffected.
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Figure 33: DROIDS Plot and Images, VsDapL and Thiobarbiturate
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300 x 0.2ns explicit solvent molecular dynamic simulation of wild type V. spinosum DapL
enzyme compared to DapL associated with a thiobarbiturate molecule. (A) Average atom
fluctuation profiles (top plot), signed symmetric Kullback-Leibler (KL) divergences in local atom
fluctuation distributions, collected from the N, CA, C and O atoms from each amino acid on the
polypeptide backbone (middle plot), and P values from a Benjamini-Hochberg corrected
Kolmogorov-Smirnov (KS) test indicating significant differences in dynamics is also shown
(bottom plot). The KL divergences in local atom fluctuation distributions are shown color
mapped to temperature on the protein structure with red indicating softer regions with amplified
fluctuation and blue indicating stabilized regions with dampened fluctuation (B) across the
entire structure and (C) on the active site. (C) P values from the KS test indicating significant
differences in dynamics.

68

8.3.5

DROIDS Summary

The differences in atomic fluctuation across the bound structure when compared to the unbound
structure of each associated compound exhibited comparable distributions of structure-wide
significance. The significant differences in fluctuation were clustered around the active sites and
dimer interface for each bound structure. The significance profiles and magnitudes of differences
in fluctuation across the structures were relatively similar. The distribution of differences in
fluctuation across the dapL structures were also relatively similar - dFLUX values ranged from 0.3 to 0.4 in a fairly consistent manner when considering only the values (Figure 34A).
The fluctuational differences when localized to the active site, however, indicate the active site
of structure bound with rhodanine exhibited more dampening than amplification. The active site
of structure bound with hydrazide, though it maintained a fairly wide distribution comparable to
that of thiobarbiturate, exhibited a lower mean of difference in fluctuation than thiobarbiturate.
The structure bound with barbiturate exhibited the highest magnitude in the distribution of
dFLUX values and the dFLUX distribution of the structure bound with thiobarbiturate was the
broadest, covering the widest range (Figure 34B).
In addition, the number of affected residues across each structure differed with each compound.
The structure bound to barbiturate resulted in the most residues exhibiting significant differences
in fluctuation (462 residues were affected), followed by thiobarbiturate (417), hydrazide (367),
and rhodanine (358) (Figure 35).
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Figure 34: Atomic Fluctuation Summary
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Plots constructed in R of (A) the differences in atomic fluctuations across the DapL structure and
(B) the differences in atomic fluctuations of active-site residues upon association with each
compound when compared to the native unbound structure.
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Figure 35: Significant fluctuation counts

Residues Experiencing Significant Changes in Fluctuation
P < 0.1 alpha
500

462

450

417

400

367

358

350
283

Count

300

239

250
206
200

202
161

156

Hydrazide

Rhodanine

179

178

Barbiturate

Thiobarbiturate

150
100
50
0

Amplified

Dampened

Total

Numbers of residues in the bound structure experiencing statistically significant differences in
fluctuation (less than 0.1 alpha) when compared to the unbound structure for each antagonistic
lead compound. Counts of residues experiencing significant amplification, dampening, and the
combined total are shown.
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Of the active site residues exhibiting significantly different magnitudes of fluctuation between
the bound and unbound structure, only a handful were either consistently amplified or dampened
in all four analyses. Residue numbers 69, 70, and 71 were amplified when VsDapL bound to all
four inhibitors and residue number 450 was dampened when VsDapL bound to all four
inhibitors. There was a higher density of amplified residues when VsDapL bound to hydrazide,
barbiturate, and thiobarbiturate and a higher density of dampened residues when VsDapL bound
rhodanine and hydrazide. In the structures bound to hydrazide and barbiturate, a large majority of
the amplified residues belonged to the active site proximal to the compound docking location,
whereas that same pocket was largely dampened in the structures bound to rhodanine and
thiobarbiturate (Figure 36). As previously mentioned, fluctuations associated with the catalytic
lysine of one active site were dampened in the structures bound to hydrazide, rhodanine, and
thiobarbiturate. It was unaffected in the structure bound to barbiturate. The fluctuations of atoms
associated with long stretches of conserved active site loops were amplified in the structure
bound to hydrazide, dampened in the structure bound to rhodanine, and amplified in the
structures bound to both barbiturate and thiobarbiturate. Relatively long stretches of conserved
active site loops exhibited fluctuation dampening in the structure bound to both hydrazide and
thiobarbiturate while short stretches of conserved active site loops exhibited fluctuation
amplification in the structure bound to rhodanine and dampening in the structure bound to
barbiturate (Table 5).
Of the four compounds selected for this study, barbiturate was the best inhibitor of vsDapL in
vitro, followed by thiobarbiturate, hydrazide, and rhodanine. DapL inhibition by barbiturate and
thiobarbiturate was ~10X higher than that by hydrazide, which exhibited ~50X higher inhibition
than rhodanine (Table 7).
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Figure 36: Summary of Affected Active Site Residues
A.
Barbiturate

Hydrazide
253 254 261 664
255 256 258
259 260 480*
486 700* 703

Rhodanine

481 485 659 660
662 667
43* 661 663

252

77* 78 79 291
294 295 595*
664

80 476 477
478 479
487 702

67 68 81 701

Thiobarbiturate

69 70 71
66 257

293 472
473 474
475 664

44* 72 73
74* 75 76
297
296 540* 796*

B.

Barbiturate

Hydrazide
44* 72 517*

Rhodanine

483* 540*
796*
73 74* 75 76
294* 295

111* 658 662
663

Thiobarbiturate

78 473 476 477
478 479 659
661 665

66 67 252 257
258 484 666

450*
77*
449*
664 698

189* 655
656
134* 249
250 251*
482 485
697

254
253 255 256
480* 481 660
699

Venn diagrams of residues that were significantly (A) amplified and (B) dampened when
comparing the bound and unbound structure for each respective inhibitory compound.
Legend: active site 1, active site 2, *Active site residue.
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Table 5: Summary of Active Site Changes in Fluctuation
Compound

Amplified

Dampened

Hydrazide

67 68 69 70 71 80 81 253 254 255
256 258 259 260 261 293 472 473 474
475 476 477 478 479 480* 486 487 664
700* 701 702 703

44* 72 73 74* 75 76 111* 134*
189* 249 250 251* 294* 295 450*
482 517* 655 656 658 662 663 697

Rhodanine

44* 66 67 68 69 70 71 72 73 74*
75 76 81 252 257 296 297 540* 701
796*

77* 78 111* 134* 249 250 251* 253
254 255 256 449* 450* 473 476 477
478 479 480* 481 482 485 658 659
660 661 662 663 664 665 697 698 699

Barbiturate

43* 44* 66 67 68 69 70 71 80 81
255 256 257 258 259 260 297 476 477
478 479 480* 481 485 486 487 659 660
661 662 663 667 700* 701 702 703

73 74* 75 76 77* 254 294* 295
449* 450* 483* 540* 664 698 796*

Thiobarbiturate

43* 44* 69 70 71 72 73 74* 75 76
77 78 79 80 291 293 294* 295 296 297
472 473 474 475 476 477 478 479 487
540* 595* 661 663 664 702 796*

66 67 134* 189* 249 250 251* 252
253 254 255 256 257 258 450* 480*
481 482 484 485 655 656 660 666 697
699

Lists of residues that exhibited changes in atomic fluctuations, whether amplification or
dampening, for each bound structure. Legend: active site 1, active site 2, *Active site residue.
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8.4

DISCUSSION

Based on RMSD (root mean square deviation) calculations of the fluctuation of the alphacarbons of each amino acid from their mean positions, the vsDapL protein is much more stable
as a homodimer. The higher and consistently rising RMSD values resulting from the monomer
dynamics indicate more instability in the system, while the constant lower RMSD values from
the dimer indicate a much more stable structure. It settles into a lowest-energy conformation and
maintains that general pattern for the duration of the simulation, as opposed to a constantly
fluctuating set of conformations. Based on the sample size and volume of data collected, we have
high confidence this trend reflects real-world scenario. In addition, considering the X-ray crystal
structures of multiple DapL enzymes and the molecular dynamics results described above, we
can conclude that DapL naturally associates into a dimer in vivo. As such, all computational
biology involving DapL (docking, molecular dynamics, etc.) should include calculations on the
homodimer. It is insufficient to assume dynamics for the system based solely on calculations
from one subunit. Any conclusions resulting from studies restricted to monomer dynamics are
not biologically relevant and cannot be taken in that context. However, because DROIDS is
equipped to not only perform the calculations on large, multi-subunit proteins, but also map the
statistics at an amino acid resolution, it provides the perfect opportunity for DapL studies.
All antagonistic compounds were successfully docked onto one active site of DapL with a
potential energy lower than DapL in its native state and with all potential energies at the same
order of magnitude (with rhodanine docking the best, followed by hydrazide and barbiturate,
with thiobarbiturate as the least effective). This indicates that all antagonistic compounds would
successfully associate with and have the potential to inhibit DapL in vivo. However, because
DapL is a homodimer, it can be speculated that the inhibitory lead compounds would bind in two
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sites. In fact, a test docking of two rhodanine molecules onto DapL indicates better binding
affinity for both together than the single molecule. In addition, it docks asymmetrically, perhaps
due to allosteric change in the structure (Figure 38). For the purpose of DROIDS, compounds
were only docked into one active site to accommodate the limitations of pre- and postcalculation processing. Though DROIDS can be applied to multi-subunit proteins, the force field
calculations for small molecules, AnteChamber, can only be applied to one molecule per file.
Because proper simulations require three files including the file containing the ligand alone in its
proper docked conformation, it can be speculated that the molecular dynamics calculations and
cpptraj processing would not account for the second ligand. Looking forward, functionality to
accommodate multiple docked ligands would be beneficial in the DROIDS software.
As expected, some areas of each protein upon binding were dampened while others experienced
an increase in fluctuation. Thus, the effect of an antagonistic lead compound, though identified to
inhibit the enzyme in vitro, is not always a dampening of protein dynamics. In some cases, the
dampening of dynamics could be linked to inhibition, but the commonly seen increase in
dynamics could indicate induced instability in the protein upon docking. Both scenarios,
theoretically, would alter binding dynamics to and reactions with the substrate to result in the
observed inhibition.
Interestingly, the docking results also did not directly reflect either the in vitro observed
inhibition or the in silico molecular dynamics analyses. Barbiturate and hydrazide docked with
the same binding affinity, but barbiturate had most significant inhibition while hydrazide was the
second least significant. Rhodanine was the worst inhibitor but docked with the best binding
affinity. Thiobarbiturate docked with the least binding affinity but was the second most
significant inhibitor. The docking position of the molecule and its interaction with neighboring
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amino acids also does not necessarily indicate areas of altered molecular dynamics. In most
cases, there was significant change in protein dynamics at or proximal to compound position,
however some changes in dynamics could not be explained by the local interactions (the changes
in protein dynamics near the compound docking location) as they occurred in distant areas of the
structure.
The molecular dynamics results support a correlation between inhibitory capacity in vitro and
overall effect on the protein in silico. Binding of the compound that inhibited DapL the most
successfully in vitro (barbiturate) resulted in the most residues that exhibited significant changes
in fluctuation, protein-wide. Binding of the second-most effective compound (thiobarbiturate)
resulted in the second-most residues exhibiting significant changes, followed by the third-most
effective (hydrazide) and the least effective (rhodanine). This correlation between molecular
dynamics and kinetics indicates DROIDS (and more broadly molecular dynamics simulations)
can successfully be used in conjunction with laboratory experiments to present both more refined
and more broadly impactful results. In addition, DROIDS could theoretically be used prior to any
experiments (via high-throughput docking of antagonistic compounds followed by molecular
dynamics of the top hits) to save time and cost of laboratory experiments or used to locate local
protein regions, domains, or conserved motifs for future study.
The field of molecular dynamics, however, must still be examined with caution as simulations
require precise and refined calculations that take into account extremely complex physical
characteristics. For example, molecules must be in their lowest potential energy wells for any
consistency or meaningful calculations. This task becomes exponentially more difficult as the
size of the molecule increases. To date, DapL is the largest protein to be analyzed with DROIDS,
and it certainly pushed the limits of the software. If the atomic coordinates were calculated for
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longer duration, or sampled for a different number of replicates, it is possible that the refined,
amino-acid resolution results would look different. For example, significance results of a 0.5ns
simulation differed slightly from those of a 0.2ns simulation for some compounds. In addition,
closely-examined active site dynamics for this study do not directly correlate with the in vitro
study. A rational prediction would indicate the highest active site dampening in the most
successful inhibitors, but the opposite was observed in silico. Complexes could be ranked as
those that maintained larger proportions of and longer stretches of statistically significant residue
dampening in both conserved active site residues and active site loops, along with less activation
in active site residues and loops, were more effective; the ranking determined by active site
dampening did not accurately reflect the in vitro data. Examining statistically significant changes
in active site molecular dynamics, the structure bound to rhodanine exhibited the highest ratio of
active site dampening to amplification, followed by hydrazide and thiobarbiturate, with
barbiturate exhibiting the lowest ratio of active site dampening to amplification. This directly
contradicts the conclusions drawn from this study and highlights the necessity of analysis
repetition, expansion, and validation.
Future work should repeat the analyses detailed above to gather more support for the conclusions
and investigate the inconsistencies regarding active site destabilization. The outlying data could
be attributed to random sampling, or it could indicate a trend toward a flaw in the analysis. In
addition, future work should include investigating the impact of mutations on binding dynamics
for insight into the potential for acquired resistance. Mutations that minimize the effect on wild
type dynamics but maximize the effect on the binding of the inhibitor would theoretically be the
most likely mutations that would contribute to resistance. Overall, though molecular dynamics is
still a newly developing field, the potential scope (as indicated by this study) is great.
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9

CONCLUSIONS

In this study, a combination of wet-bench work and bioinformatics tools was used to gain a
comprehensive perspective on the DapL enzyme for evaluation of its potential as a narrow
spectrum antibiotic target. Though it is narrowly distributed in bacteria (identified in 13% of all
genomes), it is present in a number of clinically important and pathogenic organisms, most
notable Chlamydia trachomatis. Because of the presence of the DapL pathway in mostly
anaerobic, obligate intracellular, or simply difficult to culture organisms, Verrucomicrobium
spinosum was identified as a putative model for evaluating the essentiality of the DapL enzyme.
However, developing a model system in an environmentally isolated organism, without much
prior research or knowledge, proved difficult. Its growth rate and properties in culture were
successfully characterized, and standards for genetic manipulation were developed. Though a
genetic mutant of the putatively essential dapL in V. spinosum was not successfully isolated,
major strides in assessing the essentiality of the gene and isolating a mutant were made. The
differential death rates seen in culture of mutants in supplemented liquid media, the inability to
culture anything on supplemented solid media, and the microscopic images taken of the different
putative mutants, when combined, support the essentiality of dapL. In fact, the gene may be so
essential and its loss so detrimental to the organism that the recovery of a mutant may be
impossible. The loss of both lysine in protein synthesis and meso-DAP in peptidoglycan
crosslinking may cause deficiencies and failures significant enough to cause instant cell death
upon gene interruption or replacement. Alternatively, the inability to isolate a mutant could also
be attributed to a flaw in methodology – whether it is unsuccessful transformations or improper
recovery and isolation.
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To supplement the wet-bench analyses, comparative molecular dynamics simulations of the V.
spinosum DapL enzyme and four antagonistic lead compounds were performed. The success in
correlating whole protein destabilization identified in silico with inhibition identified in vitro
supports the efficacy of using such a tool in conjunction with or prior to laboratory experiments
to refine compound identification and analysis. However, the volume and ambiguity in the data
highlights the need for verification and validation of any large-scale analyses via wet-bench
experiments. Proper care in maintaining the biologically relevant perspective must be taken to
ensure the data is not skewed, misinterpreted, or simply wrong. When proper steps are taken,
powerful and elegant conclusions can be drawn about the dynamic behavior, essentiality, and
interactions of proteins and enzymes of interest. In the case of this study, though the essentiality
of DapL was not explicitly proven, support for its essentiality was found and the effect of four
antagonistic lead compounds on the dynamic behavior of the enzyme was successfully
characterized.
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6205457

6206245

Loose

catB8

32.69

phenicol antibiotic
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chloramphenicol

Start
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Term

% ID
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Resistance Mechanism

AMR Family

acetyltransferase (CAT)

ABIZ01000001.1_4980

Contig
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Table 6: RGI CARD Scan

The identification of a gene in V. spinosum homologous to a gene conferring chloramphenicol

resistance.
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Figure 37: Rhodanine Double Docking

Ligand

Binding Affinity (kcal/mole)

rmsd/ub

rmsd/lb

VsDapL_1A

-8.5

0

0

VsDapL_2A

-8.1

43.936

40.674

VsDapL_3A

-8.1

3.163

2.227

VsDapL_4A

-8

2.248

1.788

VsDapL_5A

-7.9

18.639

16.279

VsDapL_6A

-7.8

46.198

43.602

VsDapL_1B

-8.4

0

0

VsDapL_2B

-7.5

46.749

44.442

VsDapL_3B

-7.2

40.06

38.123

VsDapL_4B

-7.2

33.441

32.209

VsDapL_5B

-7.1

33.272

31.882

VsDapL_6B

-7

37.817

36.146

(A) The structure of two rhodanine molecules (red) associated with the VsDapL enzyme (blue).
(B) Docking results for the double rhodanine and VsDapL association. The lowest energy
structure is reported first for each molecule (A and B), and the RMSD of the following structures
is reported as compared to the position of the first conformation.
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Figure 38: Full list of dampened and activated residues for each MD run
A. Hydrazide
Amplified

Dampened

5 6 36 37 41 42 45 46 47 48 49 50 51 52
53 54 55 56 57 58 67 68 69 70 71 80 81
82 85 86 89 90 92 93 94 95 96 102 103 104
105 106 107 108 128 198 207 208 209 227 228
229 230 231 232 233 234 235 236 237 238 239
240 247 253 254 255 256 258 259 260 261 262
263 267 284 285 286 287 293 311 312 313 314
315 316 317 318 319 320 321 322 323 325 326
355 356 357 393 394 395 396 397 398 399 400
401 402 403 405 411 414 415 417 418 419 420
424 446 447 448 459 460 463 467 468 471 472
473 474 475 476 477 478 479 480 486 487 489
495 496 497 503 504 505 512 513 514 530 535
536 542 543 544 546 547 550 551 552 555 556
557 558 559 560 561 562 567 568 577 578 582
583 584 603 604 605 606 611 616 617 624 664
677 678 679 680 681 682 683 685 686 700* 701
702 703 705 707 721 742 761 762 763 800 801
802

11 12 14 15 16 19 22 23 26 27 30 31 32
33 44 63 72 73 74 75 76 98 110 111 112 113
114 115 116 117 118 119 120 121 122 133 134
135 136 138 139 140 142 143 149 150 151 152
153 155 156 157 158 167 168 169 172 173 175
176 178 179 185 186 187 188 189 210 217 218
219 220 221 222 223 224 249 250 251 269 270
271 272 273 274 275 276 277 278 294 295 348
358 375 381 382 383 384 409 410 413 422 442
443 450 451 452 453 454 455 482 516 517 518
519 520 521 522 523 524 525 526 527 528 529
532 538 554 564 570 576 590 591 598 599 614
637 653 654 655 656 658 662 663 668 669 691
693 694 697 709 716 785 786 788 789 790 791
792 815 816

B. Rhodanine
Amplified

Dampened

44 45 47 64 65 66 67 68 69 70 71 72 73
74 75 76 81 82 83 85 86 89 90 91 98 99
101 102 106 108 115 163 166 167 168 169 170
171 172 173 186 187 188 192 193 194 226 240
241 252 257 265 266 267 268 269 271 272 273
274 275 277 278 282 285 286 287 288 289 296
297 308 309 310 311 312 314 315 339 340 341
342 351 352 353 354 386 387 411 413 414 415
416 417 418 419 420 421 422 423 432 433 434
435 436 437 438 439 440 441 442 444 445 446
453 471 494 495 496 497 498 499 500 501 502
503 504 505 511 512 519 530 536 538 539 540
541 542 544 546 547 548 549 550 551 552 553
569 577 578 579 582 583 592 593 600 601 602
625 626 627 628 629 630 631 641 677 678 679

5 6 7 8 9 11 12 13 14 15 16 17 18 19
20 21 22 23 24 25 26 27 28 29 30 31 32
33 34 35 36 37 38 41 53 54 57 58 77* 78
109 110 111 112 113 116 117 118 119 122 123
124 130 133 134 146 150 151 152 153 154 155
176 177 178 210 212 247 249 250 251 253 254
255 256 299 300 302 303 304 356 357 381 394
398 409 448 449 450 451 452 458 459 460 462
463 464 467 473 476 477 478 479 480 481 482
485 514 515 520 521 522 532 555 556 557 558
559 560 561 562 563 564 609 633 636 637 658
659 660 661 662 663 664 665 687 688 689 690
691 692 695 696 697 698 699 742 743 744 745
761 762 763 764 799 801
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680 681 682 683 701 710 714 715 716 717 718
719 720 721 722 723 724 730 731 733 734 750
751 752 756 771 774 775 781 783 795 796 816

C. Barbiturate
Amplified

Dampened

5 6 7 8 9 10 11 12 27 28 29 30 31 32
33 34 35 36 37 38 39 40 41 43 44 45 50
51 52 53 54 55 56 57 58 59 60 61 62 63 64
65 66 67 68 69 70 71 80 81 82 83 85 86
91 109 110 114 124 130 132 145 146 147 148 149
150 151 152 153 154 155 156 157 158 159 161
165 169 176 177 178 179 210 211 212 221 222
231 248 255 256 257 258 259 260 267 270 271
272 273 274 277 297 298 299 300 301 302 303
304 305 306 307 308 309 310 311 312 313 314
315 316 317 318 319 324 325 326 327 328 329
344 353 354 362 363 364 365 366 367 368 369
370 371 372 373 374 382 383 406 409 410 414
454 455 456 457 458 459 460 462 465 466 467
470 471 476 477 478 479 480 481 485 486 487
488 496 504 505 506 507 508 509 510 511 512
513 516 518 519 536 568 569 570 573 574 578
584 585 586 588 589 601 602 605 606 607 608
609 610 611 612 613 616 617 618 619 620 621
632 633 634 635 636 637 638 639 640 641 642
643 644 645 646 647 648 649 651 659 660 661
662 663 667 668 669 670 671 672 673 674 675
676 680 681 682 683 684 685 700 701 702 703
704 707 708 709 710 711 712 716 717 718 719
720 721 722 723 803 804 805 806

13 14 15 17 18 48 73 74 75 76 77 95 96
97 98 112 115 116 117 118 120 122 171 172 173
174 175 194 196 197 198 199 201 202 203 237
238 239 240 254 262 265 266 275 276 281 282
289 290 294 295 387 411 412 413 416 417 418
419 421 422 423 424 425 426 427 428 429 430
431 432 433 434 435 436 437 438 439 440 441
443 444 446 448 449 450 451 452 453 483 497
498 500 501 502 521 526 529 540 541 542 547
548 549 550 551 552 553 554 555 556 557 558
559 560 561 562 563 564 596 597 627 664 689
690 691 692 698 714 745 746 747 748 749 757
758 759 760 761 762 763 764 765 766 767 768
769 770 771 772 773 774 775 776 777 778 779
780 781 782 783 784 785 786 787 788 789 790
791 792 793 794 795 796 797 798 811 812 813

D. Thiobarbiturate
Amplified

Dampened

16 19 32 33 34 35 36 37 39 40 42 43 44
47 48 49 50 51 53 54 69 70 71 72 73 74
75 76 77 78 79 80 81 82 83 84 85 86 87 88
89 90 91 92 93 94 95 96 97 99 100 101 102
103 104 105 106 107 115 123 124 125 146 176
177 178 234 235 239 240 241 266 267 268 274

5 6 7 8 9 10 11 12 13 25 26 27 41 62
63 65 66 67 110 122 126 128 129 130 132 133
134 147 148 149 150 151 152 153 154 155 156
157 158 159 160 161 168 169 170 171 172 179
186 187 188 189 190 196 199 200 201 212 215
217 218 219 225 226 227 228 229 246 247 248
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287 288 289 290 291 293 294 295 296 297 305
310 311 312 314 315 338 339 353 358 359 360
361 362 363 378 379 381 382 383 384 385 386
409 413 414 415 420 421 422 423 424 425 426
427 428 429 430 431 432 433 434 435 436 437
438 439 440 441 442 443 444 445 446 448 452
470 471 472 473 474 475 476 477 478 479 487
488 501 502 503 504 505 509 513 518 539 540
541 542 551 552 563 564 565 573 574 575 576
581 582 595 596 597 598 599 600 614 615 616
637 646 647 653 661 663 664 674 675 678 702
704 705 725 726 737 740 741 742 743 744 745
746 747 753 758 769 770 771 772 773 774 775
776 777 778 779 780 781 782 783 786 791 792
794 795 796 797 798 799 800 801 802 803

249 250 251 252 253 254 255 256 257 258 270
271 276 277 278 356 357 411 416 417 418 419
450 451 455 456 457 480 481 482 484 485 493
494 497 519 520 521 522 523 524 525 526 527
528 529 531 535 536 545 546 558 559 560 561
562 587 621 622 623 624 625 626 654 655 656
660 666 680 681 682 685 686 687 688 689 690
691 692 693 694 695 696 697 699 708 709 710
711 712 713 714 715 716 717 718 719 720 761
762 763 764 787 788 789 814 815 816

Numbers of vsDapL residues that experienced significant changes in atomic fluctuation when
bound with (A) hydrazide (B) rhodanine (C) barbiturate and (D) thiobarbiturate.

Table 7: VsDapL Inhibition

Compound

IC50 Value

Hydrazide

47

Rhodanine

250

Barbiturate

4.7

Thiobarbiturate

5.7

Inhibition of the VsDapL enzyme as defined by IC50 value for the four compounds used in this
study. Adapted from (McKinnie et al., 2014).
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